港股异动 | 映恩生物-B(09606)尾盘涨超4% 与罗氏合作BD新突破潜在里程碑金额超10亿美元

智通财经09-08

智通财经APP获悉，映恩生物-B(09606)尾盘涨超4%。截至发稿，涨3.56%，报186.4港元，成交额1.94亿港元。消息面上，近日，映恩生物与罗氏集团旗下Genentech签署合作许可协议，依托公司DUPAC平台开发多款肿瘤适应症下一代ADC药物。根据合作协议，映恩生物将收取4500万美元的首付款，并有资格就所有合作项目收取总额超过10亿美元的潜在开发、监管及商业化里程碑付款。此外，公司将...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2665432393?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-09-08 15:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2665432393","market":"sh","top_or_hot":-1,"title":"港股异动 | 映恩生物-B(09606)尾盘涨超4% 与罗氏合作BD新突破 潜在里程碑金额超10亿美元","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，映恩生物-B(09606)尾盘涨超4%。截至发稿，涨3.56%，报186.4港元，成交额1.94亿港元。消息面上，近日，映恩生物与罗氏集团旗下Genentech签署合作许可协议，依托公司DUPAC平台开发多款肿瘤适应症下一代ADC药物。根据合作协议，映恩生物将收取4500万美元的首付款，并有资格就所有合作项目收取总额超过10亿美元的潜在开发、监管及商业化里程碑付款。此外，公司将...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1493292.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 映恩生物-B(09606)尾盘涨超4% 与罗氏合作BD新突破 潜在里程碑金额超10亿美元</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 映恩生物-B(09606)尾盘涨超4% 与罗氏合作BD新突破 潜在里程碑金额超10亿美元\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-09-08 15:58 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1493292.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，映恩生物-B(09606)尾盘涨超4%。截至发稿，涨3.56%，报186.4港元，成交额1.94亿港元。消息面上，近日，映恩生物与罗氏集团旗下Genentech签署合作许可协议，依托公司DUPAC平台开发多款肿瘤适应症下一代ADC药物。根据合作协议，映恩生物将收取4500万美元的首付款，并有资格就所有合作项目收取总额超过10亿美元的潜在开发、监管及商业化里程碑付款。此外，公司将...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1493292.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KCAI","symbol_name":"KraneShares China Alpha Index ETF","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1493292.html","article_id":"2665432393","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2665432393","pubTimestamp":1788854320,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，映恩生物-B尾盘涨超4%。截至发稿，涨3.56%，报186.4港元，成交额1.94亿港元。消息面上，近日，映恩生物与罗氏集团旗下Genentech签署合作许可协议，依托公司DUPAC平台开发多款肿瘤适应症下一代ADC药物。根据合作协议，映恩生物将收取4500万美元的首付款，并有资格就所有合作项目收取总额超过10亿美元的潜在开发、监管及商业化里程碑付款。同时，公司已与多家全球药企达成合作，首付款、里程碑付款及潜在销售分成有望构成长期收入来源。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"KCAI":"KraneShares China Alpha Index ETF","HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","09606":"映恩生物-B","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","BK4585":"ETF&股票定投概念","BK4588":"碎股","BK1161":"生物科技","VXUS":"国际股票ETF-Vanguard"},"translate_title":"Hong Kong Stocks in Focus | Yingen Bio-B (09606) Surges Over 4% in Late Trading After Breakthrough in BD Collaboration with Roche, Potential Milestone Exceeding US$1 Billion","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KCAI":1.5,"VXUS":1.5,"09606":1.5},"content_text":"智通财经APP获悉，映恩生物-B(09606)尾盘涨超4%。截至发稿，涨3.56%，报186.4港元，成交额1.94亿港元。消息面上，近日，映恩生物与罗氏集团旗下Genentech签署合作许可协议，依托公司DUPAC平台开发多款肿瘤适应症下一代ADC药物。根据合作协议，映恩生物将收取4500万美元的首付款，并有资格就所有合作项目收取总额超过10亿美元的潜在开发、监管及商业化里程碑付款。此外，公司将有权就合作所产生获批产品的年度净销售额收取分层特许权使用费。中信建投发布研报称，公司是国内领先的创新型ADC药物研发平台公司，已构建DITAC、DIMAC、DIBAC及DUPAC四大技术平台。DB-1311已进入全球Ⅲ期临床，并积极拓展“ADC+IO2.0”联用及多瘤种适应症；DB-1303逐步进入注册兑现期，DB-1418、DB-1317及DB-2304等创新管线持续推进。同时，公司已与多家全球药企达成合作，首付款、里程碑付款及潜在销售分成有望构成长期收入来源。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2665432393","isCrawlerRequest":true}

港股异动 | 映恩生物-B(09606)尾盘涨超4% 与罗氏合作BD新突破 潜在里程碑金额超10亿美元

精彩评论

港股异动 | 映恩生物-B(09606)尾盘涨超4% 与罗氏合作BD新突破潜在里程碑金额超10亿美元